Clinical Trial

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98%BERKELEY, Calif. and MAINZ, Germany,…

7 months ago

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3…

7 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating,…

7 months ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive…

7 months ago

Rose Hill Life Sciences to Spotlight Leading Research Partners at Psychedelic Science 2025

Dr. Gül Dölen, MD, PhD, to share groundbreaking research on how psychedelic compounds can reopen “critical periods” of brain plasticity.…

7 months ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

7 months ago

Vivani Medical to Present at the 2025 BIO International Convention

ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical…

7 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the…

7 months ago

Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data at Clinical Trials at the Summit and MaculArt

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a…

7 months ago

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care

Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy® (semaglutide 7.2 mg) for those…

7 months ago